Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737024 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL3269280 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL3269278 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL7737022 | 1.00 | MAPT (0.38) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL20969242 | 0.96 | MAPT (0.36) | MAPTGAAMEN1KMT2ADRD1 | |
| SCHEMBL3270112 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL1574998 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL13293543 | 0.90 | CYP2C9 (0.42) | MAPTMEN1KMT2AOPRL1CYP2C9 | |
| SCHEMBL12733579 | 0.87 | MAPT (0.38) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL18559471 | 0.87 | MAPT (0.42) | MAPTGAAMEN1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458433-B1 | ISOTOPE REPLACEMENT; OPTICAL DISPLAY | CHISSO CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020038858-A1 | Isotope replacement; optical display | JNC CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
| EP-0949232-A1 | DIFLUOROPHENYL DERIVATIVES, LIQUID-CRYSTAL COMPOUNDS, AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038858-A1 | Isotope replacement; optical display | IRS1, FES, IK | MAPT 600/4885GAA 4848/4885MEN1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.